Results 71 to 80 of about 22,314 (175)

No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine—a prospective multicenter study by the Polish Adult Leukemia Group

Frontiers in Oncology
IntroductionInfections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia <
Krzysztof Mądry, Karol Lis, Elzbieta Sienkiewicz, Joanna Drozd-Sokołowska, Przemysław Biecek, Oktawia Sośnia, Aleksandra Gołos, Magdalena Olszewska-Szopa, Agata Obara, Zuzanna Walkowiak, Joanna Ściesińska, Edyta Subocz, Aleksandra Butrym, Rafał Machowicz, Katarzyna Budziszewska, Grzegorz Basak   +15 more
doaj   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]

Eur J Haematol
ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Vigna E, Bruzzese A, Martino EA, Corsonello A, Caserta S, Labanca C, Mendicino F, Lucia E, Olivito V, Amodio N, Morabito F, Gentile M.   +11 more
europepmc   +2 more sources

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms [PDF]

, 2011
Background: Alterations in the DNA methylation pattern are a hallmark of leukemias and lymphomas. However, most epigenetic studies in hematologic neoplasms (HNs) have focused either on the analysis of few candidate genes or many genes and few HN entities,
Agirre, Xabier, Alvarez, Sara, Ammerpohl, Ole, Bibikova, Marina, Brüggemann, Monika, Bug, Stefanie, Calasanz, Maria J., Cruz Cigudosa, Juan, Deckert, Martina, Dreyling, Martin, Du, Ming Q., Dyer, Martin J. S., Dürig, Jan, Fan, Jian-Bing, Gesk, Stefan, Haferlach, Claudia, Hansmann, Martin-Leo, Harder, Lana, Hartmann, Sylvia, Klapper, Wolfram, Küppers, Ralf, Martin-Subero, Jose Ignacio, Montesinos-Rongen, Manuel, Nagel, Inga, Pott, Christiane, Prosper, Felipe, Richter, Julia, Román-Gómez, José, Seifert, Marc, Siebert, Reiner, Stein, Harald, Suela, Javier, Trümper, Lorenz, Vater, Inga, Wickham-Garcia, Eliza   +34 more
core  

Understanding drugs in breast cancer through drug sensitivity screening [PDF]

, 2015
With substantial numbers of breast tumors showing or acquiring treatment resistance, it is of utmost importance to develop new agents for the treatment of the disease, to know their effectiveness against breast cancer and to understand their ...
Foekens, J.A. (John), Göhlmann, H.W.H. (Hinrich W. H.), Heine, A.A.J. (Anouk), Jager, A. (Agnes), Martens, J.W.M. (John), Ozturk, B. (Bahar), Prager-van der Smissen, W.J.C. (Wendy), Smid, M. (Marcel), Uhr, K. (Katharina)   +8 more
core   +4 more sources

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

HASH(0x563d44119a08) [PDF]

, 2009
HASH(0x563d44067a70)HASH ...
Nachtnebel, A.
core  

The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases

Frontiers in Pharmacology
BackgroundAzacitidine is used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It acts as a cytosine analog and DNA methyltransferase inhibitor, inducing DNA hypomethylation to reverse epigenetic modifications and restore normal ...
Zhaorui Wang, Linlin Guo, Youfu He, Baiquan Zhang, Yang Wang, Juan Ding   +5 more
doaj   +1 more source

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal [PDF]

, 2016
Report commissioned by the NIHR HTA ProgrammeThis report was commissioned by the NIHR HTA Programme as project number 15/64 ...
Cooper, C, Hoyle, MW, Mujica-mota, R, Rudin, C, Rule, S, Snowsill, T, Tikhonova, I, Varley-Campbell, J   +7 more
core